Market Cap | 211.21M | P/E | - | EPS this Y | 47.30% | Ern Qtrly Grth | - |
Income | -117.17M | Forward P/E | -2.28 | EPS next Y | 6.90% | 50D Avg Chg | 30.00% |
Sales | 3.6M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 119.00% |
Dividend | N/A | Price/Book | 1.34 | EPS next 5Y | - | 52W High Chg | -10.00% |
Recommedations | 2.00 | Quick Ratio | 3.87 | Shares Outstanding | 20.76M | 52W Low Chg | 295.00% |
Insider Own | 1.20% | ROA | -32.14% | Shares Float | 10.61M | Beta | 0.88 |
Inst Own | 88.49% | ROE | -88.43% | Shares Shorted/Prior | 1.20M/889.95K | Price | 2.10 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 531,745 | Target Price | 35.33 |
Oper. Margin | -3,437.97% | Earnings Date | Aug 8 | Volume | 406,951 | Change | -5.83% |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Truist Securities | Buy | May 15, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Apr 30, 24 |
Mizuho | Buy | Apr 29, 24 |
Chardan Capital | Buy | Mar 19, 24 |
RBC Capital | Sector Perform | Mar 19, 24 |
Mizuho | Buy | Feb 6, 24 |
Mizuho | Buy | Nov 2, 23 |
Truist Securities | Buy | Sep 5, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Seyedkazemi Setareh | Chief Development Of.. Chief Development Officer | Sep 15 | Sell | 1.53 | 6,201 | 9,488 | 47,674 | 09/18/23 |
Beckman Richard | Chief Medical Office.. Chief Medical Officer | Sep 19 | Sell | 1.0697 | 4,272 | 4,570 | 39,061 | 09/21/22 |
Seyedkazemi Setareh | Chief Development Of.. Chief Development Officer | Sep 19 | Sell | 1.0696 | 6,058 | 6,480 | 47,875 | 09/21/22 |
Soparkar Peter | See Remarks section See Remarks section | Sep 19 | Sell | 1.0697 | 13,305 | 14,232 | 273,251 | 09/21/22 |
Riley Brigit | Chief Scientific Off.. Chief Scientific Officer | Sep 19 | Sell | 1.0697 | 7,266 | 7,772 | 118,734 | 09/21/22 |
Fischer Laurent | CEO, President and D.. CEO, President and Director | Sep 19 | Sell | 1.0696 | 41,082 | 43,941 | 727,380 | 09/21/22 |
Beckman Richard | Chief Medical Office.. Chief Medical Officer | May 17 | Buy | 0.8228 | 10,000 | 8,228 | 10,000 | 05/19/22 |
D'Souza Rupert | Chief Financial Offi.. Chief Financial Officer | May 13 | Buy | 0.84 | 20,000 | 16,800 | 20,850 | 05/17/22 |
Fischer Laurent | CEO, President and D.. CEO, President and Director | Apr 20 | Buy | 1.112 | 25,000 | 27,800 | 762,462 | 04/22/22 |
Soparkar Peter | See Remarks section See Remarks section | Apr 19 | Buy | 1.14 | 21,925 | 24,994 | 280,556 | 04/20/22 |
Fischer Laurent | CEO, President and D.. CEO, President and Director | Dec 08 | Buy | 1.82 | 25,000 | 45,500 | 737,462 | 12/10/21 |
PATTERSON LEONE D | President and CFO President and CFO | Feb 11 | Sell | 14.12 | 12,533 | 176,966 | 97,955 | 02/11/21 |